Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
25 hedge funds and large institutions have $1.19M invested in Navidea Biopharmaceuticals Inc. in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 10 reducing their positions, and 7 closing their positions.
19% less funds holding
Funds holding: 31 → 25 (-6)
29% less capital invested
Capital invested by funds: $1.68M → $1.19M (-$489K)
78% less call options, than puts
Call options by funds: $60K | Put options by funds: $270K
80% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 10
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
+$57.5K |
| 2 |
Morgan Stanley
New York
|
+$186 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$51K |
| 2 |
Two Sigma Advisers
New York
|
-$45.3K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$37.6K |
| 4 |
Two Sigma Investments
New York
|
-$33K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$13.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCMLT
26
Beacon Capital Management LLC (Tennessee)
Franklin,
Tennessee
| – | +$9 | +10 | New |
|
|
27
Morgan Stanley
New York
| – | +$186 | +203 | +64% |
|
NAVB Hedge Fund Activity: Q1 2022 in Review
25 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q1 2022, worth a combined $1.19M — down 29% from $1.68M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of NAVB and 1 opened new positions — a net loss of 6 holders — while 10 trimmed existing stakes and 2 added.
The largest buyer was Group One Trading, adding an estimated $57.5K. The largest seller was Commonwealth Equity Services, exiting entirely with an estimated $51K sold.
- 25 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q1 2022, down from 31 in Q4 2021.
- Funds reported $1.19M of Navidea Biopharmaceuticals Inc. stock for Q1 2022, down 29% quarter-over-quarter.
- 1 fund opened new Navidea Biopharmaceuticals Inc. positions in Q1 2022 and 7 closed out, a net change of -6 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q1 2022 was Group One Trading, an estimated $57.5K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q1 2022 was Commonwealth Equity Services, an estimated $51K sold.
Based on aggregated 13F filings for Q1 2022.